SCND · Scientific Industries Inc
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for at least one year after the date the Unaudited Condensed Consolidated Financial Statements are issued. The Company has recorded recurring losses from operations and continued cash outflow from operating activities as a result of its strategic focus on the Bioprocessing Systems Operations, which is still in its start-up stage. Historically the Company has relied on equity financings to support its business operations. For the six months ended June 30, 2026, the Company generated negative cash flows from operations of $1,897,600. The Company has an accumulated deficit of $37,974,000 as of June 30, 2026, and expects to continue to generate negative cash flows from operations in the foreseeable future; however, based on management's current operating plan, the Company expects that the cash generated from the Laboratory Equipment Operations' Genie Division sale during fiscal 2025 (refer to Note 11), plus other incoming cash related to the various post Genie Division-sale agreements and escrow account, is sufficient to support business operations for at least one year from the date of issuance of the Unaudited Condensed Consolidated Financial Statements for the six months ended June 30, 2026; however, there is no assurance that management's current operating plan will be successful.”View the 10-Q filed Aug 14, 2026
2 customers — 49% of revenue (the three months ended June 30, 2026)
“For the three months ended June 30, 2026, two customers accounted for approximately 49% of the Company’s total revenue.”
2 customers — 35% of revenue (the six months ended June 30, 2026)
“For the six months ended June 30, 2026, two customers accounted for approximately 35% of the Company’s total revenue.”
One customer — 10% of revenue (the six months ending June 30, 2025)
“For the six months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
One customer — 10% of revenue (the three months ending June 30, 2025)
“For the three months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-20 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
14,700 |
| 2026-06-02 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
4,000 |
| 2026-03-23 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
9,000 |
| 2026-02-19 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
1,000 |
| 2026-02-17 | MOORE JOHN A |
Director, Chairman |
Award↑
|
Stock Option
|
30,000 |
| 2026-02-17 | NICOLS JOHN J |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On 2/17/26 Registrant was awarded stock options in lieu of cash fees. Vesting 1 Year - 1/12th per month. |
Stock Option
|
120,000 |
| 2026-02-17 | Rovinsky Zachary |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
Vesting is based on 4 year cliff from date of option grant. |
Stock Option
|
25,000 |
| 2026-02-17 | BLECHMAN MICHAEL |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
Options granted to Registrant in lieu of cash fees. Vesting 1 year - 1/12th per month. |
Stock Option
|
24,000 |
| 2026-02-17 | MOORE JOHN A |
Director, Chairman |
Award↑
Filing footnotes — Stock Option (Direct)
Options granted to Registrant in lieu of cash compensation. Vesting is 1 year - 1/12th per month. |
Stock Option
|
230,000 |
| 2026-02-17 | SANTOS HELENA R |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Direct)
Vesting is based on 4 year cliff from date of option grant. |
Stock Option
|
130,000 |
| 2026-02-17 | SANTOS HELENA R |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Direct)
Options granted to Registrant in lieu of salary. Vesting 1 year - 1/12th per month. |
Stock Option
|
50,000 |
| 2026-02-17 | NICOLS JOHN J |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
On 2/17/26 Registrant was awarded stock options in lieu of cash fees. Vesting 1 Year - 1/12th per month. |
Stock Option
|
20,000 |
| 2026-02-17 | BLECHMAN MICHAEL |
Director |
Award↑
|
Stock Option
|
20,000 |
| 2025-12-17 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
6,500 |
| 2025-12-17 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
11,700 |
| 2025-12-05 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
20,000 |
| 2025-09-17 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
5,800 |
| 2025-09-16 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
9,599 |
| 2025-08-20 | MOORE JOHN A |
Director, Chairman |
Award↑
Filing footnotes — Common Stock (Direct)
On August 20, 2025, 30,000 warrants for 30,000 shares of the Company's common stock were exercised at $1.00 per share. |
Common Stock
|
30,000 |
| 2025-08-20 | NICOLS JOHN J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
On August 20, 2025 15,000 warrants for 15,000 shares of the Company's common stock were exercised at $1.00 per share. |
Common Stock
|
15,000 |
| 2025-08-20 | BLECHMAN MICHAEL |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
On August 20, 2025, 10,000 warrants for 10,000 shares of the Company's Common Stock were exercised at $1.00 per share. |
Common Stock
|
10,000 |
| 2025-05-13 | MOORE JOHN A |
Director, Chairman |
Award↑
Filing footnotes — Stock Option (Direct)
1/4 of the option shares vest one year from issue date, the balance of the shares vest in a series of thirty six (36) equal monthly installments measured from the first anniversary date of the issue date. |
Stock Option
|
65,000 |
| 2025-05-13 | SANTOS HELENA R |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Direct)
1/4 of the option shares vest one year from issue date, the balance of the shares vest in a series of thirty six (36) equal monthly installments measured from the first anniversary date of the issue date. |
Stock Option
|
70,000 |
| 2025-04-18 | NICOLS JOHN J |
Director |
Buy↑
Filing footnotes — Warrant to Purchase Common Stock (Direct)
On April 18, 2025 Registrant purchased from Scientific Industries, Inc. (the "Issuer") for an aggregate purchase price of $15,000, 15,000 shares of Common Stock and warrants to acquire 15,000 shares of Common Stock at an exercise price of $1.00 per share. |
Warrant to Purchase Common Stock
|
15,000 |
| 2025-04-18 | Bleichroeder LP |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
On April 18, 2025, 21 April Fund, Ltd. and 21 April Fund, LP agreed to purchase from Scientific Industries Inc. (the "Issuer"), for an aggregate purchase price of $250,000, 250,000 shares of Common Stock and warrants to acquire 250,000 shares of Common Stock at an exercise price of $1.00 per share. This form is filed by Bleichroeder LP. Bleichroeder LP serves as registered investment adviser to 21 April Fund, Ltd., 21 April Fund, LP and other managed accounts. Bleichroeder LP disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder LP is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. |
Common Stock
(I)
|
250,000 |
| 2025-04-18 | NICOLS JOHN J |
Director |
Buy↑
|
Common Stock
|
15,000 |
| 2025-04-18 | BLECHMAN MICHAEL |
Director |
Buy↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
On April 18, 2025 Registrant purchased from Scientific Industries, Inc. (the "Issuer") for an aggregate purchase price of $10,000, 10,000 shares of Common Stock and warrants to acquire 10,000 shares of Common Stock at an exercise price of $1.00 per share. |
Warrants to Purchase Common Stock
|
10,000 |
| 2025-04-18 | Bleichroeder LP |
10% Owner |
Buy↑
Filing footnotes — Warrants to Purchase Common Stock (Indirect)
On April 18, 2025, 21 April Fund, Ltd. and 21 April Fund, LP agreed to purchase from Scientific Industries Inc. (the "Issuer"), for an aggregate purchase price of $250,000, 250,000 shares of Common Stock and warrants to acquire 250,000 shares of Common Stock at an exercise price of $1.00 per share. This form is filed by Bleichroeder LP. Bleichroeder LP serves as registered investment adviser to 21 April Fund, Ltd., 21 April Fund, LP and other managed accounts. Bleichroeder LP disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder LP is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. |
Warrants to Purchase Common Stock
(I)
|
250,000 |
| 2025-04-18 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
35,000 |
| 2025-04-18 | MOORE JOHN A |
Director, Chairman |
Buy↑
Filing footnotes — Warrant to Purchase Common Stock (Direct)
On April 18, 2025 Registrant purchased from Scientific Industries, Inc. (the "Issuer") for an aggregate purchase price of $35,000, 35,000 shares of Common Stock and warrants to acquire 35,000 shares of Common Stock at an exercise price of $1.00 per share. |
Warrant to Purchase Common Stock
|
35,000 |
| 2025-04-18 | BLECHMAN MICHAEL |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2024-10-31 | MOORE JOHN A |
Director, Chairman |
Buy↑
Filing footnotes — Common Stock (Direct)
Includes 128,082 shares of Common Stock, 286,134 Options to Purchase Common Stock, and 65,556 Warrants to Purchase Common Stock. |
Common Stock
|
7,000 |
| 2024-07-01 | NICOLS JOHN J |
Director |
Award↑
|
Option to Purchase Common Stock
|
5,000 |
| 2024-07-01 | NICOLS JOHN J |
Director |
Award↑
|
Option to Purchase Common Stock
|
10,000 |
| 2024-07-01 | Cox Christopher T |
Director |
Award↑
|
Option to Purchase Common Stock
|
5,000 |
| 2024-07-01 | Cox Christopher T |
Director |
Award↑
|
Option to Purchase Common stock
|
10,000 |
| 2024-07-01 | BLECHMAN MICHAEL |
Director |
Award↑
|
Option to Purchase Common Stock
|
5,000 |
| 2024-07-01 | SCHUMACHER JURGEN WALTER |
Director |
Award↑
|
Option to Purchase Common Stock
|
10,000 |
| 2024-06-13 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
9,200 |
| 2024-06-13 | MOORE JOHN A |
Director, Chairman |
Buy↑
|
Common Stock
|
7,100 |
| 2024-05-17 | BLECHMAN MICHAEL |
Director |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
Options vest in three successive equal installments from 5/17/24 as to 1/3 on each of the first, second, and third anniversaries. |
Options to Purchase Common Stock
|
25,000 |
| 2024-05-17 | BLECHMAN MICHAEL |
Director |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
On May 17, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid part of his fees in lieu of cash compensation. These options vest in twelve monthly installments commencing on May 17, 2024 through May 17, 2025. |
Options to Purchase Common Stock
|
7,186 |
| 2024-04-01 | SANTOS HELENA R |
Director, President and CEO |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
On April 1, 2024, the Reporting Person and the Issuer entered into an agreement whereby the Reporting Person elected to be paid part of her salary in stock options in lieu of cash compensation. These options vest in twelve monthly installments commencing on April 1, 2024 through April 1, 2025. |
Options to Purchase Common Stock
|
55,100 |
| 2024-04-01 | SCHUMACHER JURGEN WALTER |
Director |
Award↑
Filing footnotes — Option to Purchase Common Stock (Direct)
On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid for Reporting Person's Board of Director fees in options in lieu of cash compensation. These options vest in twelve monthly installments commencing on April 1, 2024. |
Option to Purchase Common Stock
|
14,371 |
| 2024-04-01 | Averilla Reginald |
CFO |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
On April 1, 2024, the Reporting Person and the Issuer entered into an agreement whereby the Reporting Person elected to be paid part of his salary in stock options in lieu of cash compensation. These options vest in twelve monthly installments commencing on April 1, 2024 through April 1, 2025. |
Options to Purchase Common Stock
|
9,768 |
| 2024-04-01 | Cox Christopher T |
Director |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid for Reporting Person's fees as a Board Director in stock options in lieu of cash compensation. These options vest in twelve (12) monthly installments commencing on April 1, 2024 through April 1, 2025. |
Options to Purchase Common Stock
|
17,964 |
| 2024-04-01 | NICOLS JOHN J |
Director |
Award↑
Filing footnotes — Option to Purchase Common Stock (Direct)
On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid for Reporting Person's fees as a Board Director in stock options in lieu of cash compensation. These options vest in twelve (12) monthly installments commencing on April 1, 2024 through April 1, 2025. |
Option to Purchase Common Stock
|
10,778 |
| 2024-04-01 | MOORE JOHN A |
Director, Chairman |
Award↑
Filing footnotes — Options to Purchase Common Stock (Direct)
On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid part of his salary in stock options in lieu of cash compensation. These options vest in twelve monthly installments commencing on April 1, 2024 through April 1, 2025. Includes 65,556 Warrants to Purchase Common Stock, and 286,134 Options to Purchase Common Stock. |
Options to Purchase Common Stock
|
58,182 |
| 2024-01-17 | SANTOS HELENA R |
Director, President and CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
Includes 1,977 warrants inclusive of 11 warrants acquired in this transaction plus 232,366 stock options. |
Common Stock
|
11 |
| 2024-01-17 | SANTOS HELENA R |
Director, President and CEO |
Buy↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
Includes 232,366 stock options and 1,977 warrants |
Warrants to Purchase Common Stock
|
11 |